13 Jan 21 | Kamada announced it has entered into agreements with two undisclosed international pharmaceutical companies to commercialise three biosimilar product candidates in Israel.
15 Jan 21 | Celltrion announced it has submitted an investigational new drug application for Ph III trials of CT-P41 (proposed denosumab biosimilar).